大健康 | 2026 年 3 月 20 日 诺和诺德 | NVO US 静待价值重估 全球代谢龙头诺和诺德 (Novo Nordisk, NVO US) 的估值修复。公司正 处于一个独特的历史交汇点：股价在 2025 年经历回调，估值压缩，市场 忽视了公司在核心糖尿病领域的稳固份额及在全球肥胖市场的长期领先 统治力。短期催化剂有产能释放带来的业绩反弹，中期有 CagriSema 和口服新药的确证性数据，长期有 Amycretin 和新适应症拓展带来的第 二营收增长空间。这种由过渡期阵痛引发的抛售，与公司长期稳健的基 本面形成背离，创造具吸引力的入场点。 2026 年估值逻辑与股价回升。模型遵循管理层-5%至-13%的指引，假设 公司 2026 年调整后销售与营业利润将可能出现分别约 -6%及-9%的下 滑。而 13 倍的 2026 年预期市盈率 (P/E)反映了市场开始透过短期负增 长的迷雾，提前定价 2027 年的反弹。13 倍 P/E 对应的是公司作为 GLP- 1 龙头的溢价，以及对利空出尽的预期。一旦 340B 尘埃落定且重组完 成，优于-13%下限的表现可能成为惊喜。2025 年的回调主要受市场对产 ...

Drug stocks can be somewhat volatile. Things like clinical setbacks or patent cliffs can sink their stock prices or erode their profits and market share. However, one good thing about companies in this industry is that there will always be a need for innovative medicines, which remain in high demand regardless of economic conditions. That makes drugmakers, particularly the best ones capable of consistently developing new products, attractive long-term holdings. Let's consider three, in particular, that look ...

Core Viewpoint - The article discusses the challenges in finding equity income, highlighting low dividend yields in both the US and global markets, and emphasizes the importance of companies with strong dividend histories and wide economic moats for steady income generation [1][2][4]. Dividend Yield Trends - The Morningstar US Market Index had a dividend yield of under 1.2% in Q1 2026, which is historically low, while the Morningstar Global Markets ex-US Index offered a yield of 2.6% [1]. - Stock prices have increased significantly, but dividend payments have not kept pace, with a notable shift towards share buybacks and investments in artificial intelligence [2]. Sector Performance - There has been a rebound in sectors such as industrials, energy, and consumer defensives, which has supported total returns but kept yields lower [3]. - Dividend-paying stocks outside the U.S. have outperformed the broader market for some time, with around 1,500 companies globally under analyst coverage and assigned moat ratings [3]. Moat Analysis - Companies with wide moats tend to sustain profitability more consistently and have historically cut dividends less often compared to those with narrow or no moats [4]. Methodology for Stock Selection - The selection criteria for the list of dividend stocks included companies that have raised dividends for at least 10 consecutive years and have yields above 0.5% as of March 19 [6]. Company Highlights - **Eli Lilly and Company (NYSE: LLY)**: - Dividend yield as of March 19 is 0.75%. Recent study results for retatrutide indicate it may be a viable option for patients prioritizing weight loss, with projected 2030 sales at $4.9 billion [9][10][11]. - **S&P Global Inc. (NYSE: SPGI)**: - Dividend yield as of March 19 is 0.91%. The price recommendation was raised to $495, citing stronger issuance trends, with February billed issuance rising 22% year-over-year [12][13]. - The acquisition of Enertel AI Corporation enhances S&P Global's capabilities in AI-driven power price forecasting, providing a more comprehensive view of the power market [14][15].

England’s drug price regulator will have to reconsider its decision to rule out using Eli Lilly’s Alzheimer’s drug in the state-run National Health Service, following a successful appeal by the US drugmaker https://t.co/fWXon8Qsap ...

In this article, we will look at the 12 Best Long Term Stocks to Invest In According to Billionaires.On March 17, Ed Yardeni, Yardeni Research president, appeared on CNBC’s ‘Squawk Box’ to talk about the impact of the Iran war, the latest market trends, and the state of the economy.He says he is more risk-averse, at least for the near-term, and stated that everybody on Wall Street is trying to be a military expert in this fog of war, when actually, even the military experts cannot accurately predict where t ...

The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark, Feb. 4, 2026.The Food and Drug Administration on Thursday approved a higher dose version of Novo Nordisk's blockbuster weight loss injection Wegovy, as the company pushes to win back market share from chief rival Eli Lilly. Novo expects to launch the higher, 7.2-milligram dose of Wegovy in April. The Danish drugmaker is positioning that version to better compete with Lilly's obesity drug Z ...

Novo Nordisk won approval to sell a high-dose version of its blockbuster Wegovy obesity shot in the US, allowing it to offer weight loss closer to that of rival Eli Lilly's competing shot Zepbound https://t.co/pUCnYjWVYd ...

整理 | GLP1减重宝典内容团队 礼来在代谢赛道又向前推了一步。 3月19日，礼来宣布，其GIPR/GLP-1R/GCGR三靶点激动剂 Retatrutide 在III期 TRANSCEND-T2D-1 研究中取得积极结果。该研究主要评估 Retatrutide 作为饮食和运动基础上的辅助治疗，用于仅靠生活方式干预仍无法良好控糖的2型糖尿病成人患者时的疗效与安全性。 从公布的数据来看，这款每周一次给药的三靶点药物，不仅达成了主要终点，也完成了所有关键次要终点。40周治疗后，Retatrutide 相较安慰 剂，在降糖和减重两大核心指标上都显示出明显优势。 其中，在主要终点方面，按疗效估计目标分析，接受 Retatrutide 治疗的患者，糖化血红蛋白 A1C 平均最高下降达到 2.0%。而在关键次要终点 方面，患者平均减重最高达到 36.6 磅，约合 16.8%。更值得注意的是，减重趋势在整个治疗过程中并未提前触顶，而是持续到研究结束。 除了血糖和体重这两项最受关注的指标，Retatrutide 在心血管代谢风险因素上也交出了不错的答卷。礼来表示，该药还带来了非高密度脂蛋白 胆固醇、甘油三酯以及收缩压等指标 ...

Patients On Lilly’s Experimental Diabetes Drug Lost 15% Of Their Weight And Lowered Blood Sugar, Company Sayshttps://t.co/ywt309vSxh https://t.co/aZiJf5Qpmu ...

Eli Lilly’s experimental weight-loss drug retatrutide met the primary and key secondary endpoints in a trial, showing significant reductions in weight loss and blood sugar levels. https://t.co/OFBUzypgGt ...